Propofol and Fentanyl Pharmacokinetics and Pharmacodynamics in Extracorporeal Membrane Oxygenation
<b>Rationale:</b> Despite the potential risks associated with sedation, there is a paucity of pharmacokinetic/pharmacodynamic (PK/PD) data for propofol and fentanyl in patients supported with venovenous extracorporeal membrane oxygenation (V-V ECMO). <b>Objective:</b> Describe propofol and fentanyl PK/PD profiles in patients receiving V-V ECMO. <b>Methods:</b> Prospective, single-center, open-label PK/PD study at the Toronto General Hospital intensive care unit between July 2022 and January 2023. Using high-performance liquid chromatography/tandem mass spectrometry, propofol and fentanyl total concentrations were measured during V-V ECMO. Sequential PK/PD modeling, using sex as a covariate, was conducted with processed electroencephalography (patient state index [PSI]) for sedation and expiratory occlusion pressure and airway occlusion pressure during the first 0.1 second for respiratory effort. <b>Results:</b> Eleven patients underwent 106 evaluations over a median follow-up of 146 (interquartile ranges, 116-146) hours. Patients' average age was 43 (standard deviation, 13) years, and 55% were female. Propofol and fentanyl PKs were best described by a two-compartment model. Propofol PSI PD were described using an effect compartment, with a coefficient of determination of 0.78. There was a significant increase in propofol (<i>P</i> = 0.01) and fentanyl (<i>P</i> = 0.03) clearance within 10 minutes of ECMO initiation, plateauing after 8 hours of ECMO support. Despite this, patient oversedation (PSI <40) occurred in 74% of the observations. Female patients exhibited a higher sedative central volume of distribution and lower propofol clearance. <b>Conclusions:</b> ECMO initiation resulted in a time-limited increased sedative clearance. PSI accurately described sedative PD, but variable respiratory effort was observed irrespective of sedative plasma concentrations. Sex-based differences were found in sedative PK/PD parameters.
Authors
- María Patricia Hernández-Mitre (ORCID: https://orcid.org/0000-0003-3565-0292)
- Diana Morales Castro (ORCID: https://orcid.org/0000-0001-9205-9613)
- Kiran Shekar (ORCID: https://orcid.org/0000-0002-1239-7514)
- Jack Uetrecht (ORCID: https://orcid.org/0000-0003-1024-1302)
- John Thomas Granton (ORCID: https://orcid.org/0000-0002-2639-5958)
- Mohd H. Abdul‐Aziz (ORCID: https://orcid.org/0000-0002-8889-5579)
- Manuel Tisminetzky (ORCID: https://orcid.org/0000-0002-8917-5266)
- Idunn S. Morris (ORCID: https://orcid.org/0000-0001-9943-1684)
- Linda Dresser
- Eric X. Chen (ORCID: https://orcid.org/0000-0002-4581-8848)
- Eleonora Balzani (ORCID: https://orcid.org/0000-0001-7837-4457)
- Irene Wong (ORCID: https://orcid.org/0000-0002-4375-3665)
- J. Turgeon (ORCID: https://orcid.org/0009-0006-5710-7847)
- K. Sandy Pang (ORCID: https://orcid.org/0000-0002-0683-2129)
- Eddy Fan (ORCID: https://orcid.org/0000-0002-1210-9914)
- Felipe Jurado-Camacho
Institutions
- 3M (United States) (US)
- The University of Queensland (AU)
- University of Toronto (CA)
- Nepean Hospital (AU)
- Toronto General Hospital (CA)
- Prince Charles Hospital (AU)
Publication Details
- Journal
- Annals of the American Thoracic Society
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1513/annalsats.202407-795oc
- Citations
- 5
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 2.24